Biotech Hangout
Episode 76
Oct 16, 2023
Biotech Hangout's Daphne Zohar, Brad Loncar, Josh Schimmer, Mike Yee & Tim Opler cover the big news: BMS' acquisition of Mirati Therapeutics, 14 biotech acquisitions over $1B, and Illumina ordered to sell Grail after acquisition deal. They discuss data from Akero, Alnylam, Ventyx, Merck, Novo Nordisk, Immunic, and PMV Pharmaceuticals. Takeaways from Jefferies CNS Day and HLTH 2023 are shared.
59:31
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- PMV Pharmaceuticals presented positive data for their P53 corrector at a conference, demonstrating promising overall response rates in multiple tumor types without K-RAS mutations.
- Merck's Keytruda showed positive overall survival data in resectable lung cancer, marking the first time a Neo-Adjuvant study with a PD-1 inhibitor has shown an overall survival advantage in this form of cancer.
Deep dives
Positive data presented for PMV Pharmaceuticals' P53 corrector
PMV Pharmaceuticals shared positive data from their study of a P53 corrector at a conference. The drug showed promising overall response rates in the 35-40% range in multiple tumor types without K-RAS mutations. Regulatory plans were also announced.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
